Amalgamated Bank Has $4.14 Million Position in Amedisys, Inc. (NASDAQ:AMED)

Amalgamated Bank reduced its stake in Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 0.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,055 shares of the health services provider’s stock after selling 97 shares during the period. Amalgamated Bank owned about 0.07% of Amedisys worth $4,144,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. HighTower Advisors LLC boosted its position in Amedisys by 23.2% during the 4th quarter. HighTower Advisors LLC now owns 5,426 shares of the health services provider’s stock worth $869,000 after buying an additional 1,021 shares during the period. Covestor Ltd acquired a new stake in Amedisys during the 4th quarter worth approximately $28,000. Schroder Investment Management Group boosted its position in Amedisys by 937.3% during the 4th quarter. Schroder Investment Management Group now owns 187,883 shares of the health services provider’s stock worth $30,415,000 after buying an additional 169,770 shares during the period. Gotham Asset Management LLC boosted its position in Amedisys by 3.5% during the 4th quarter. Gotham Asset Management LLC now owns 11,168 shares of the health services provider’s stock worth $1,808,000 after buying an additional 381 shares during the period. Finally, Sio Capital Management LLC acquired a new stake in Amedisys during the 4th quarter worth approximately $2,428,000. 93.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Stock Performance

Shares of AMED stock opened at $111.00 on Thursday. The firm has a market capitalization of $3.60 billion, a PE ratio of 25.87, a price-to-earnings-growth ratio of 2.90 and a beta of 0.95. The firm has a fifty day simple moving average of $121.75 and a two-hundred day simple moving average of $129.77. The company has a current ratio of 0.92, a quick ratio of 0.92 and a debt-to-equity ratio of 0.43. Amedisys, Inc. has a 12 month low of $101.61 and a 12 month high of $188.88.

Amedisys (NASDAQ:AMEDGet Rating) last announced its quarterly earnings results on Wednesday, July 27th. The health services provider reported $1.47 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.24. The business had revenue of $557.89 million during the quarter, compared to analyst estimates of $583.12 million. Amedisys had a net margin of 6.33% and a return on equity of 17.81%. Amedisys’s quarterly revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.69 EPS. Analysts forecast that Amedisys, Inc. will post 5.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. UBS Group downgraded shares of Amedisys from a “neutral” rating to a “sell” rating and cut their target price for the stock from $145.00 to $95.00 in a research report on Tuesday, August 2nd. Jefferies Financial Group restated a “buy” rating and issued a $200.00 price target on shares of Amedisys in a research report on Tuesday, June 28th. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Amedisys from $210.00 to $175.00 and set a “buy” rating on the stock in a research report on Tuesday, June 21st. Stifel Nicolaus started coverage on shares of Amedisys in a research report on Tuesday, June 28th. They issued a “hold” rating and a $128.00 price target on the stock. Finally, SVB Leerink dropped their price target on shares of Amedisys from $117.00 to $107.00 and set a “market perform” rating on the stock in a research report on Tuesday, June 21st. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $156.25.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Further Reading

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.